GLP-1 and SGLT-2 Drugs Together Slash Artery Aging Markers in Diabetics
Combining liraglutide and empagliflozin cut carotid plaque thickness by 10.7% and slashed amyloid-β by 50.7% over 12 months in T2DM patients.
Summary
A 12-month prospective study in 183 type 2 diabetes patients compared insulin, liraglutide (GLP-1RA), empagliflozin (SGLT-2i), and their combination on vascular aging markers. All treatments reduced carotid intima-media thickness (cIMT) and amyloid-β1-40, but the GLP-1/SGLT-2 combination delivered the largest improvements. The combo therapy achieved cIMT regression below the high-risk threshold in 75% of patients versus only 40% on insulin. Oxidative stress, measured by malondialdehyde, fell most sharply with GLP-1-based regimens. Patients whose arteries regressed also showed dramatically greater drops in amyloid-β, suggesting a linked biological mechanism between vascular and amyloid pathology that newer diabetes drugs appear to beneficially target.
Detailed Summary
Cardiovascular disease remains the leading cause of death in type 2 diabetes, and structural markers like carotid intima-media thickness (cIMT) are well-validated proxies for atherosclerotic burden and vascular age. Emerging evidence also links circulating amyloid-β1-40 to vascular injury and cognitive risk, making it an intriguing dual target in metabolic disease management.
This prospective, propensity-score-matched study enrolled 183 metformin-treated type 2 diabetes patients and assigned them to 12 months of insulin, liraglutide, empagliflozin, or the liraglutide-empagliflozin combination. Researchers measured six-segment cIMT at baseline, 6, and 12 months, alongside plasma amyloid-β1-40 and malondialdehyde (MDA) as markers of amyloid-related vascular injury and oxidative stress respectively.
All four regimens reduced cIMT and amyloid-β1-40, but the newer agents dramatically outperformed insulin. The combination therapy reduced cIMT by 10.7% versus just 1.7% for insulin, and amyloid-β1-40 by 50.7% versus 30.7%. Three-quarters of combination-treated patients achieved cIMT below the 1.5 mm high-risk threshold, compared to 54% on empagliflozin alone, 67% on liraglutide alone, and 40% on insulin. MDA reductions were greatest in GLP-1RA-containing regimens, pointing to antioxidant mechanisms as a key contributor.
A notable finding was the correlation between cIMT regression and amyloid-β1-40 reduction, suggesting these pathways are mechanistically intertwined. This raises the possibility that reducing vascular amyloid burden may be part of how these drugs protect the cardiovascular system — and potentially the brain.
Caveats include the relatively small sample size, the single-center design, and reliance on propensity-score matching rather than full randomization. Longer follow-up would be needed to determine whether these surrogate marker improvements translate into reduced cardiovascular events or cognitive outcomes.
Key Findings
- Liraglutide + empagliflozin reduced carotid IMT by 10.7% vs. only 1.7% with insulin over 12 months.
- 75% of combination-therapy patients achieved low-risk cIMT below 1.5 mm vs. 40% on insulin.
- Amyloid-β1-40 dropped 50.7% with combination therapy vs. 30.7% with insulin.
- GLP-1-based regimens produced the largest reductions in oxidative stress marker malondialdehyde.
- Carotid plaque regression was significantly correlated with drops in both amyloid-β1-40 and MDA.
Methodology
Prospective, propensity-score-matched study of 183 metformin-treated T2DM patients across four treatment arms over 12 months. Six-segment carotid IMT was assessed at baseline, 6, and 12 months; plasma amyloid-β1-40 and malondialdehyde were measured as biomarkers. The propensity-score matching aimed to reduce selection bias, though it does not fully substitute for randomization.
Study Limitations
The study is single-center with a relatively small cohort, limiting generalizability. Propensity-score matching reduces but does not eliminate confounding compared to a randomized controlled trial. The 12-month follow-up is insufficient to determine whether surrogate marker improvements translate to hard cardiovascular or cognitive endpoints.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: